Designing Treatment Plans for Patients With Plaque Psoriasis

This activity will explore factors informing the diagnosis of plaque psoriasis and differentiation from other skin disorders, the clinical utility of novel therapies, and strategies for employing a comprehensive approach to designing individualized care plans for patients with plaque psoriasis. Start the activity now!

STATEMENT OF NEED

Plaque psoriasis is the most common type of psoriasis, a chronic dermatologic disease characterized by patches of thick red skin and silvery scales, which are often pruritic. Approximately 3% of adults aged 20 years or older in the United States are affected by plaque psoriasis, with significant variation by race and ethnicity (Armstrong et al, 2021). A variety of drug classes with different efficacy and safety profiles, routes of administration, and dosing schedules are now available for the treatment of plaque psoriasis. In order to optimize outcomes for individual patients, it is crucial for members of the interprofessional medical care team to remain up to date on emerging therapies and adverse event management and to incorporate effective patient education and shared decision making into their practice. This activity will explore factors informing the diagnosis of plaque psoriasis and differentiation from other skin disorders, the clinical utility of novel therapies, and strategies for employing a comprehensive approach to designing individualized care plans for patients with plaque psoriasis. 

TARGET AUDIENCE

Dermatologists, primary care physicians, nurse practitioners, physician assistants/associates, nurses, pharmacists, and other healthcare providers involved in the treatment of adults with plaque psoriasis.

Upon completion of this activity, participants should be able to:

• Differentiate plaque psoriasis from other skin disorders
• Evaluate the clinical utility of novel therapies for individual adults with plaque psoriasis
• Utilize a comprehensive approach to care for adults with plaque psoriasis

PROVIDED BY

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 6/18/2025. PAs should only claim credit commensurate with the extent of their participation. 

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development 

A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 1.0 ANCC contact hour of pharmacology credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour.

Continuing Pharmacy Education

i3 Health has approved this knowledge-based activity for 1.0 ACPE CE hour. The Universal Activity Number for this activity is JA0008128-0000-24-005-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion. 

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Laurel Ranger has no relevant financial relationships to disclose.

Eden E.D. Maack, PhD, has no relevant financial relationships to disclose

i3 Health has mitigated all relevant financial relationships.